New drug duo aims to shrink tumors before cancer surgery
NCT ID NCT07457281
Summary
This early-stage study is testing a new two-drug combination (GV20-0251 plus sintilimab) given to patients before surgery for head and neck cancer. The main goals are to find a safe dose and see if the treatment can shrink the tumors, which is measured by examining the tissue removed during surgery. The study will enroll about 9 adults with a specific type of head and neck cancer that can be surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.